data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Pro Streamline Promotional Ad

25% Off Benzinga's Most Powerful Trading Tools

Traders Win More with Benzinga's Exclusive News and Squawk

Pro Streamline Promotional Ad

Pro Streamline Promotional Ad

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Bayer

(OTCPK:BAYRY)

Intraday

Perks Buy Compare Brokers

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Bayer Stock (OTC:BAYRY)

Bayer Stock (OTC: BAYRY)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, April 10, 2024

Alphabet, Nasdaq, Spotify, Teck Resources And A Major Financial Stock On CNBC's 'Final Trades'
Avi Kapoor - Apr 10, 2024, 9:13AM

Tuesday, April 09, 2024

Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists
Vandana Singh - Apr 9, 2024, 2:13PM

Friday, April 05, 2024

Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds
Piero Cingari - Apr 5, 2024, 12:24PM

Tuesday, March 19, 2024

Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
Vandana Singh - Mar 19, 2024, 9:31AM

Thursday, March 14, 2024

German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
Vandana Singh - Mar 14, 2024, 3:59PM

Wednesday, March 06, 2024

Boundless Bio Files For IPO; Applies To List Its Common Stock On Nasdaq Under Symbol "BOLD"
Benzinga Newsdesk - Mar 6, 2024, 4:58PM

Tuesday, March 05, 2024

Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges
Vandana Singh - Mar 5, 2024, 3:25PM

Monday, March 04, 2024

What's Going On With BridgeBio Pharma Stock On Monday?
Vandana Singh - Mar 4, 2024, 12:31PM
BridgeBio Pharma And Bayer Announce European Licensing Agreement For Acoramidis In ATTR-CM, BridgeBio To Receive $310M Plus Royalties
Benzinga Newsdesk - Mar 4, 2024, 2:34AM

Tuesday, January 30, 2024

Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial
Vandana Singh - Jan 30, 2024, 7:49AM

Monday, January 29, 2024

Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout
Vandana Singh - Jan 29, 2024, 9:41AM

Thursday, January 11, 2024

Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
Vandana Singh - Jan 11, 2024, 11:40AM

Monday, January 08, 2024

Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial
Vandana Singh - Jan 8, 2024, 1:11PM

Thursday, January 04, 2024

Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial
Vandana Singh - Jan 4, 2024, 10:57AM

Wednesday, January 03, 2024

Top Stocks, Sectors Loved By Congress Members Who Traded In 2023: Apple, NVIDIA, Microsoft, Ford And More Stocks To Watch In 2024
Chris Katje - Jan 3, 2024, 11:29AM

Tuesday, December 26, 2023

Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak
Vandana Singh - Dec 26, 2023, 6:58AM

Tuesday, December 19, 2023

ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US
Surbhi Jain - Dec 19, 2023, 8:59AM

Wednesday, December 06, 2023

Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss
Vandana Singh - Dec 6, 2023, 12:49PM

Monday, December 04, 2023

Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion
Vandana Singh - Dec 4, 2023, 1:39PM

Tuesday, November 28, 2023

PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
Natan Ponieman - Nov 28, 2023, 2:47PM

Friday, November 24, 2023

German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
Vandana Singh - Nov 24, 2023, 12:48PM

Monday, November 20, 2023

Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Vandana Singh - Nov 20, 2023, 2:58PM
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Vandana Singh - Nov 20, 2023, 1:34PM

Friday, November 17, 2023

Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
Vandana Singh - Nov 17, 2023, 6:05AM

Tuesday, November 14, 2023

AI Is Pharma's Newest Power Tool For Enhancing Clinical Trials
Upwallstreet - Nov 14, 2023, 12:59PM

Thursday, November 09, 2023

Bayer And Recursion Focus Research Collaboration On Oncology; Leverage Bayer's Small Molecule Compound Library And Expertise In Biology And Medicinal Chemistry As Well As Recursion's Purpose-Built AI-Guided Drug Discovery Platform
Benzinga Newsdesk - Nov 9, 2023, 9:44AM

Wednesday, November 08, 2023

Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
Vandana Singh - Nov 8, 2023, 11:15AM

Wednesday, November 01, 2023

Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
Vandana Singh - Nov 1, 2023, 1:31PM

Friday, October 13, 2023

Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles
The Bamboo Works - Oct 13, 2023, 9:32AM

Friday, September 22, 2023

AI To Revolutionize Clinical Trials And Diagnostics
Upwallstreet - Sep 22, 2023, 12:51PM
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Vandana Singh - Sep 22, 2023, 7:49AM

Thursday, September 21, 2023

Hologic, Bayer Announce International Partnership For Contrast-Enhanced Mammography Package To Breast Imaging Facilities
Benzinga Newsdesk - Sep 21, 2023, 8:35AM

Thursday, September 14, 2023

Bayer's New CEO Plans To Cut Management Jobs In Prelude To Overhaul
Benzinga Newsdesk - Sep 14, 2023, 11:59AM

Tuesday, September 12, 2023

FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
Vandana Singh - Sep 12, 2023, 4:06PM

Monday, August 28, 2023

Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Vandana Singh - Aug 28, 2023, 10:37AM
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
Vandana Singh - Aug 28, 2023, 10:02AM

Monday, August 21, 2023

FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
Vandana Singh - Aug 21, 2023, 8:37AM

Tuesday, August 08, 2023

As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
David Willey - Sponsored
Bayer Lowered Its FY23 Outlook, Now Sees Sales Of €48.5B-€49.5B (Previous View €51B-€52B); Expects Core Earnings Per Share Of €6.20-€6.40 (Previous View €7.20-€7.40)
Benzinga Newsdesk - Aug 8, 2023, 3:00AM
Bayer Q2 EPS $0.33 Beats $0.31 Estimate, Sales $12.04B Miss $12.56B Estimate
Benzinga Newsdesk - Aug 8, 2023, 2:52AM

Monday, July 31, 2023

Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema
Vandana Singh - Jul 31, 2023, 9:43AM

Monday, July 17, 2023

Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment
David Willey - Sponsored

Thursday, June 29, 2023

AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
Vandana Singh - Jun 29, 2023, 1:39PM

Wednesday, June 28, 2023

Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study
Vandana Singh - Jun 28, 2023, 9:20AM
Experimental Stem Cell Therapy For Parkinson's Shows Promise in Phase I Trial: Reuters
Benzinga Newsbot - Jun 28, 2023, 8:03AM

Tuesday, June 27, 2023

Unmasking Q2 2023's Stars & Strugglers: Industry ETFs And Top Stock Standouts
Piero Cingari - Jun 27, 2023, 9:33AM

Friday, June 23, 2023

Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Vandana Singh - Jun 23, 2023, 2:18PM

Thursday, June 08, 2023

Perrigo Picks Former Bayer Executive As New CEO
Lekha Gupta - Jun 8, 2023, 9:38AM

Monday, April 24, 2023

Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
Vandana Singh - Apr 24, 2023, 8:19AM

Thursday, April 20, 2023

'Activist Investor Ramps Up Pressure On Incoming Bayer Boss; Bluebell Capital Partners Is Pushing For The Break-Up Of Bayer And Supervisory Board Reshuffle' - Financial Times
Benzinga Newsdesk - Apr 20, 2023, 10:23AM

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved